Allozymes
Singapore, Singapore· Est.
AI‑powered microfluidic platform for rapid, scalable enzyme discovery and industrial biosolutions.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered microfluidic platform for rapid, scalable enzyme discovery and industrial biosolutions.
PharmaceuticalsIndustrial BiotechnologyFood & NutritionDiagnostics
Technology Platform
Proprietary ultra‑high‑throughput microfluidic droplet screening combined with AI‑driven enzyme database (ZymeLeap™) for rapid design, testing, and scale‑up of biocatalysts.
Opportunities
Expanding demand for sustainable biocatalysis across pharma, chemicals, and food creates strong growth potential for Allozymes’ enzyme‑as‑a‑service and licensing models.
Risk Factors
Commercial adoption depends on proving cost‑effectiveness at scale and competing with established players like Ginkgo Bioworks and Zymergen.
Competitive Landscape
Allozymes differentiates through its ultra‑high‑throughput microfluidic platform and massive enzyme data set, but faces competition from other synthetic biology and enzyme engineering firms that also offer AI‑driven design and scale‑up capabilities.